ANNA PROTOPAPAS is listed as an executive officer and director on 3 SEC Form D filings by 1 issuer between Mar 2015 and Jun 2016: Mersana Therapeutics, Inc. (Cambridge, MA — biotechnology — 2015–2016; $33.1M reported sold to 13 investors).
What this means One deal on file with the SEC. A Form D is the notice a company files after it starts selling a private investment — it is a notice, not an approval.
Listed alongside DONALD BERGSTROM (3 shared filings), David Mott (3 shared filings), ELAINE JONES (3 shared filings), EVA JACK (3 shared filings), Sara Nayeem (3 shared filings) and 5 others.
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around ANNA. Each name links to their own page.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AK, AL, AR, AZ, CA, CT, DE, FINRA, GA, HI, ID, IL, KS, KY, LA, MA, MD, ME, MI, MO, MS, MT, NASAA, NC, ND, NH, NM, NV, OK, OR, PA, RI, SC, SD, TN, TX, VT, WA, WI, WV, WY) — 2 court cases matching the name listed in Key records below.
What this means 2 records came back. Each one is listed below with a link to the original document and a line saying why it matched. A name match is not proof it is the same person or company — read the why line and the document. Being sued or named in a release is an accusation, not a finding.
We compared 3 public filings for ANNA PROTOPAPAS and found 2 differences: No amendment in the last 12 months on an offering that may still be open; ANNA PROTOPAPAS's role changed at Mersana Therapeutics, Inc.: executive officer → executive officer, director.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.